Jianjun Gao, MD, PhD

Peer-Reviewed Articles

1. Gao J, Ward JF, Pettaway CA, Shi LZ, Subudhi SK, Vence LM, Zhao H, Chen J, Chen H, Efstathiou E, Troncoso P, Allison JP, Logothetis CJ, Wistuba II, Sepulveda MA, Sun J, Wargo J, Blando J, Sharma P. VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nat Med 23 (5) :551-555, 2017. PMID: 28346412.
2. Biebighauser KC, Gao J, Rao P, Landon G, Pagliaro L, Dinney CPN, Karam J, Navai N. Non-seminomatous germ cell tumor with bone metastasis only at diagnosis: A rare clinical presentation. Asian J of Urol 4:124-127, 2016.
3. Bilen MA, Subudhi SK, Gao J, Tannir NM, Tu SM, Sharma P. Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody. J Immunother Cancer 4:36, 2016. PMID: 27330809.
4. Liu XD, Hoang A, Zhou L, Kalra S, Yetil A, Sun M, Ding Z, Zhang X, Bai S, German P, Tamboli P, Rao P, Karam JA, Wood C, Matin S, Zurita A, Bex A, Griffioen AW, Gao J, Sharma P, Tannir N, Sircar K, Jonasch E. Resistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor Microenvironment in Metastatic Renal Cell Carcinoma. Cancer Immunol Res 3 (9) :1017-29, 2015. PMID: 26014097.
5. Chen H, Fu T, Suh WK, Tsavachidou D, Wen S, Gao J, Ng Tang D, He Q, Sun J, Sharma P. CD4 cells require ICOS-mediated P13K-signaling to increase T-bet expression in the setting of anti-CTLA therapy. Cancer Immunol Res 2 (2) :167-76, 2014. PMID: 24778280.
6. Gou HF, Li X, Qiu M, Cheng K, Li LH, Dong H, Chen Y, Tang Y, Gao F, Zhao F, Men HT, Ge J, Su JM, Xu F, Bi F, Gao JJ, Liu JY. Epidermal growth factor receptor (EGFR)-RAS signaling pathway in penile squamous cell carcinoma. PLoS One 8 (4) :e62175, 2013. PMID: 23637996.
7. Gao JJ, Shen J, Kolbert C, Raghavakaimal S, Papasian CJ, Qureshi AA, Vogel SN, Morrison DC, Qureshi N. The proteasome regulates bacterial CpG DNA-induced signaling pathways in murine macrophages. Shock 34 (4) :390-401, 2010. PMID: 20160661.
8. Shen J, Gao JJ, Zhang G, Tan X, Morrison DC, Papasian C, Vogel SN, Qureshi N. Proteasome-mediated regulation of CpG DNA- and peptidoglycan-induced cytokines, inflammatory genes, and mitogen-activated protein kinase activation. Shock 25 (6) :594-9, 2006. PMID: 16721267.
9. Gao JJ, Diesl V, Wittmann T, Morrison DC, Ryan JL, Vogel SN, Follettie MT. Bacterial LPS and CpG DNA differentially induce gene expression profiles in mouse macrophages. J Endotoxin Res 9 (4) :237-43, 2003. PMID: 12935354.
10. Papasian CJ, Silverstein R, Gao JJ, Bamberger DM, Morrison DC. Anomalous role of tumor necrosis factor alpha in experimental enterococcal infection. Infect Immun 70 (12) :6628-37, 2002. PMID: 12438335.
11. Gao JJ, Diesl V, Wittmann T, Morrison DC, Ryan JL, Vogel SN, Follettie MT. Regulation of gene expression in mouse macrophages stimulated with bacterial CpG-DNA and lipopolysaccharide. J Leukoc Biol 72 (6) :1234-45, 2002. PMID: 12488506.
12. Chi L, Li Y, Stehno-Bittel L, Gao J, Morrison DC, Stechschulte DJ, Dileepan KN. Interleukin-6 production by endothelial cells via stimulation of protease-activated receptors is amplified by endotoxin and tumor necrosis factor-alpha. J Interferon Cytokine Res 21 (4) :231-40, 2001. PMID: 11359654.
13. Gao JJ, Xue Q, Zuvanich EG, Haghi KR, Morrison DC. Commercial preparations of lipoteichoic acid contain endotoxin that contributes to activation of mouse macrophages in vitro. Infect Immun 69 (2) :751-7, 2001. PMID: 11159964.
14. Gao JJ, Xue Q, Papasian CJ, Morrison DC. Bacterial DNA and lipopolysaccharide induce synergistic production of TNF-alpha through a post-transcriptional mechanism. J Immunol 166 (11) :6855-60, 2001. PMID: 11359845.
15. Gao JJ, Filla MB, Lorsbach RB, Pace JL, Crespo A, Russell SW, Murphy WJ. Prolonged exposure of mouse macrophages to IFN-beta suppresses transcription of the inducible nitric oxide synthase gene: altered availability of transcription factor Stat1alpha. Eur J Immunol 30 (6) :1551-61, 2000. PMID: 10898490.
16. Chu W, Gao J, Murphy WJ, Hunt JS. A candidate interferon-gamma activated site (GAS element) in the HLA-G promoter does not bind nuclear proteins. Hum Immunol 60 (11) :1113-8, 1999. PMID: 10600009.
17. Gao JJ, Zuvanich EG, Xue Q, Horn DL, Silverstein R, Morrison DC. Cutting edge: bacterial DNA and LPS act in synergy in inducing nitric oxide production in RAW 264.7 macrophages. J Immunol 163 (8) :4095-9, 1999. PMID: 10510342.
18. Gao JJ, Filla MB, Fultz MJ, Vogel SN, Russell SW, Murphy WJ. Autocrine/paracrine IFN-alphabeta mediates the lipopolysaccharide-induced activation of transcription factor Stat1alpha in mouse macrophages: pivotal role of Stat1alpha in induction of the inducible nitric oxide synthase gene. J Immunol 161 (9) :4803-10, 1998. PMID: 9794412.
19. Gao J, Morrison DC, Parmely TJ, Russell SW, Murphy WJ. An interferon-gamma-activated site (GAS) is necessary for full expression of the mouse iNOS gene in response to interferon-gamma and lipopolysaccharide. J Biol Chem 272 (2) :1226-30, 1997. PMID: 8995425.
20. Subudhi SK, Aparicio A, Gao J, Zurita AJ, Araujo JC, Logothetis CJ, Tahir SA, Korivi BR, Slack RS, Vence L, Emerson RO, Yusko E, Vignali M, Robins HS, Sun J, Allison JP, Sharma P. Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities. Proc Natl Acad Sci U S A 113 (42) :11919-11924. PMID: 27698113.
21. Gao J, Shi LZ, Zhao H, Chen J, Xiong L, He Q, Chen T, Roszik J, Bernatchez C, Woodman SE, Chen PL, Hwu P, Allison JP, Futreal A, Wargo JA, Sharma P. Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy. Cell 167 (2) :397-404.e9. PMID: 27667683.
22. Kim C, Gao J, Shannon VR, Siefker-Radtke A. Systemic sarcoidosis first manifesting in a tattoo in the setting of immune checkpoint inhibition. BMJ Case Rep 2016. PMID: 27797838.
23. Gao JJ, Maricque BB, Morse MD, Huang W, McNeel DG. Identification of autoantibodies in a patient with testicular cancer and concurrent inflammatory bowel disease. J Clin Oncol 28 (33) :e680-3. PMID: 20805455.
24. Reuben A, Gittelman RM, Gao J, Zhang J, Yusko E, Wu CJ, Emerson R, Zhang J, Tipton CM, Li J, Quek K, Gopalakrishnan V, Chen R, Vence L, Cascone T, Vignali M, Fujimoto J, Rodriguez-Canales J, Parra ER, Little LD, Gumbs C, Forget MA, Federico L, Haymaker C, Behrens C, Benzeno S, Bernatchez C, Sepesi B, Gibbons DL, Wargo JA, William WN, Swisher SG, Heymach J, Robins H, Lee JJ, Sharma P, Allison JP, Futreal PA, Wistuba II, Zhang J. TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: an Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence. Cancer Discov. PMID: 28733428.
25. Shah AY, Karam JA, Malouf GG, Rao P, Lim ZD, Jonasch E, Xiao L, Gao J, Vaishampayan UN, Heng DY, Plimack ER, Guancial EA, Fung C, Lowas SR, Tamboli P, Sircar K, Matin SF, Kimryn Rathmell W, Wood CG, Tannir NM. Management and outcomes of patients with renal medullary carcinoma: a multicentre collaborative study. BJU Int. PMID: 27860149.
26. Malouf GG, Su X, Yao H, Gao J, Xiong L, He Q, Compérat E, Couturier J, Molinié V, Escudier B, Camparo P, Doss DJ, Thompson EJ, Khayat D, Wood CG, Yu W, Teh BT, Weinstein J, Tannir NM. Next-generation sequencing of translocation renal cell carcinoma reveals novel RNA splicing partners and frequent mutations of chromatin-remodeling genes. Clin Cancer Res 20 (15) :4129-40. PMID: 24899691.
27. Shi LZ, Fu T, Guan B, Chen J, Blando JM, Allison JP, Xiong L, Subudhi SK, Gao J, Sharma P. Interdependent IL-7 and IFN-γ signalling in T-cell controls tumour eradication by combined α-CTLA-4+α-PD-1 therapy. Nat Commun 7:12335. PMID: 27498556.

Invited Articles

1. Campbell MT, Siefker-Radtke AO, Gao J. The state of immune check point inhibition in urothelial carcinoma: current evidence and future areas of exploration. Cancer J 22 (2) :96-100, 2016. PMID: 27111904.
2. Gao J, He Q, Subudhi S, Aparicio A, Zurita-Saavedra A, Lee DH, Jimenez C, Suarez-Almazor M, Sharma P. Review of Immune-Related Adverse Events in Prostate Cancer Patients Treated with Ipilimumab: MD Anderson Experience. Oncogene 34 (43) :5411-7, 2015. e-Pub 2015. PMID: 25659583.
3. Siefker-Radtke AO, Gao J. Towards effective adjuvant treatment for urothelial cancer. Lancet Oncol 16 (1) :9-10, 2015. PMID: 25498220.
4. Jonasch E, Gao J, Rathmell WK. Renal cell carcinoma. BMJ 349 (10) :g4797, 2014. PMID: 25385470.
5. Lizée G, Overwijk WW, Radvanyi L, Gao J, Sharma P, Hwu P. Harnessing the power of the immune system to target cancer. Annu Rev Med 64:71-90, 2013. PMID: 23092383.
6. Gao J, Bernatchez C, Sharma P, Radvanyi LG, Hwu P. Advances in the development of cancer immunotherapies. Trends Immunol 34 (2) :90-8, 2013. PMID: 23031830.
7. Lei MG, Gao JJ, Morrison DC, Qureshi N. Pathogenesis of sepsis: current concepts and emerging therapies. Mo Med 100 (5) :524-9, 2003. PMID: 14601445.

Abstracts

1. Gao J, Ward JF, Pettaway CA, Subudhi SK, Vence LM, Zhao H, Chen J, Chen H, Efstathiou E, Troncoso P, Allison JP, Logothetis C, Wistuba II, Wargo JA, Blando JM, Sepulveda MA, Sun JJ, Sharma P. Investigation of mechanisms of resistance to ipilimumab therapy with a pre-surgical trial in patients with high-risk, localized prostate cancer. J Clin Oncol, 2017.
2. Subudhi SK, Aparicio A, Troncoso P, Zhang Jianhua, Gumbs C, Wu CJ, Gao J, Vence LM, Blando JM, Corn PG, Araujo JC, Zurita AJ, Prokhorova IN, Van Alstine M, Logothetis C, Futreal A, Allison JP, Sharma P. Linking tumor mutational load to clinical responses to ipilimumab (IPI) in men with advanced prostate cancer (PCa). ASCO Annual Meeting, 2017.
3. Subudhi SK, Aparicio A, Troncoso P, Zhang Jianhua, Gumbs C, Wu CJ, Gao J, Vence LM, Blando JM, Corn PG, Araujo JC, Zurita AJ, Prokhorova IN, Van Alstine M, Logothetis C, Futreal A, Allison JP, Sharma P. Linking tumor mutational load to clinical responses to ipilimumab (IPI) in men with advanced prostate cancer (PCa). J Clin Oncol 35 (suppl) , 2017.
4. Gao J, Karam JA, Wood CG, Matin S, Ahrar K, Jonasch E, Tannir N, Campbell M, Ng C, Slack R, Rao P, Allison JP, Blando JM, Vence LM, Basu S, Zhao H, Chen T, Chen H, Sharma P. Clinical activity, immune and molecular correlates of nivolumab vs. nivolumab plus bevacizumab vs nivolumab plus ipilimumab in metastatic renal cell carcinoma. AACR Annual Meeting, 2017.
5. Gao J, Ward JF, Pettaway CA, Subudhi SK, Vence LM, Zhao H, Chen J, Chen H, Efstathiou E, Troncoso P, Allison JP, Logothetis C, Wistuba II, Wargo JA, Blando JM, Sepulveda MA, Sun JJ, Sharma P. Investigation of mechanisms of resistance to ipilimumab therapy with a pre-surgical trial in patients with high-risk, localized prostate cancer. ASCO Annual Meeting, 2017.
6. Gao J, Malouf GG, Su X, Yao H, Rao P, He R, Xiong L, Karam JA, Matin SF, Mouawad R, Comperat E, Khayat D, Wood CG, Tannir NM. Molecular profiling of renal medullary carcinoma to reveal frequent alterations in chromatin remodeling genes and to identify EZH2 as a relevant therapeutic target. ASCO Annual Meeting, 2016.
7. Subudhi SK, Aparicio A, Gao J, Zurita-Saavedra A, Araujo J, Logothetis CJ, Brinda KR, Allison JP, Vence L, Emerson RO, Yusko E, Vignali M, Robins HS, Sung J, Sharma P. Exploratory biomarkers that predict for clinical outcomes in a Phase II trial with ipilimumab plus finite androgen deprivation therapy for metastatic non-castrate prostate cancer. AACR Annual Meeting, 2016.
8. Mmeje CO, Slade A, Slack R, Navai N, Gao J, Siefker-Radtke AO, Kamat AM, Dinner CPN, Shah JB. The utility of neutrophil-to-lymphocyte ratio in determining survival outcomes in patients treated with neoadjuvant chemotherapy and radical cystectomy for high-risk bladder cancer. GU ASCO Annual Meeting, 2016.
9. Subudhi SK, Aparicio A, Gao J, Zurita-Saavedra A, Araujo J, Logothetis CJ, Brinda KR, Allison JP, Vence L, Emerson RO, Yusko E, Vignali M, Robins HS, Sung J, Sharma P. Exploratory biomarkers that predict for clinical outcomes in a Phase II trial with ipilimumab plus finite androgen deprivation therapy for metastatic non-castrate prostate cancer. Cancer Res, 2016.
10. Campbell MT, McConkey DJ, Matin SF, Kamat AM, Dinner CPN, Wang J, Gao J, Siefker-Radtke AO. The hotspot mutational landscape of upper tract and bladder urothelial cancers and correlation to survival. J Clin Oncol 34 (suppl 2s) , 2016.
11. Gao J, Malouf GG, Su X, Yao H, Rao P, He R, Xiong L, Karam JA, Matin SF, Mouawad R, Comperat E, Khayat D, Wood CG, Tannir N. Molecular profiling of renal medullary carcinoma to reveal frequent alterations in chromatin remodeling genes and to identify EZH2 as a relevant therapeutic target. GU ASCO Annual Meeting, 2016.
12. Shah AY, Karam JA, Rao, P, Jonasch E, Rathmell K, Matin SF, Vaishampayan UN, Heng D, Plimack ER, Guancial EA, Fung C, Lowas SR, Lim ZD, Wood CG, Tannir NM. Management and outcomes of patients with renal medullary carcinoma (RMC): A collaborative multi-center study of 52 patients. ASCO Annual Meeting, 2016.
13. Campbell MT, McConkey DJ, Matin SF, Kamat AM, Dinner CPN, Wang J, Gao J, Siefker-Radtke AO. The hotspot mutational landscape of upper tract and bladder urothelial cancers and correlation to survival. GU ASCO Annual Meeting, 2016.
14. Shah, AY, Karam JA, Malouf GG, Rao P, Lim ZD, Jonasch E, Xiao L, Gao J, Vaishampayan UN, Heng DYC, Plimack ER, Guancial EA, Fung C, Lowas SR, Tamboli P, Sircar K, Matin SF, Rathemell K, Wood CG, Tannir NM. Management and outcomes of patients with renal medullary carcinoma (RMC): A collaborative multi-center study of 52 patients. J Clin Oncol 34 (suppl) , 2016.
15. Mmeje CO, Slade A, Slack R, Navai N, Gao J, Siefker-Radtke AO, Kamat AM, Dinner CPN, Shah JB. The utility of neutrophil-to-lymphocyte ratio in determining survival outcomes in patients treated with neoadjuvant chemotherapy and radical cystectomy for high-risk bladder cancer. J Clin Oncol 34 (suppl 2s) , 2016.
16. Gao J, Malouf GG, Su X, Yao H, Rao P, He R, Xiong L, Karam JA, Matin SF, Mouawad R, Comperat E, Khayat D, Wood CG, Tannir NM. Molecular profiling of renal medullary carcinoma to reveal frequent alterations in chromatin remodeling genes and to identify EZH2 as a relevant therapeutic target. J Clin Oncol 34 (suppl) , 2016.
17. Gao J, Malouf GG, Su X, Yao H, Rao P, He R, Xiong L, Karam JA, Matin SF, Mouawad R, Comperat E, Khayat D, Wood CG, Tannir N. Molecular profiling of renal medullary carcinoma to reveal frequent alterations in chromatin remodeling genes and to identify EZH2 as a relevant therapeutic target. J Clin Oncol 34 (suppl 2s) , 2016.
18. Gao J, Shi LZ, Xiong L, He Q, Chen J, Shen DY, Sharma P. Expression of IFNgR on tumor cells impact response to anti-CTLA-4. AAI Annual Meeting, 2015.
19. Mmeje CO, Benson C, Nogueras-Gonzalez GM, Jayaratna IS, Navai N, Gao J, Siefker-Radtke AO, Kamat AM, Dinney CP, Shay JB. Determining the optimal timing for radical cystectomy after neoadjuvant chemotherapy. J Clin Oncol 33 (suppl 7) , 2015.
20. Liu X, Hoang A, Zhou L, Kalra S, Yetil A, Sun M, Ding Z, Tamboli P, Rao P, Karam JA, Wood CG, Matin SF, Zurita AJ, Bex A, Griffioen AW, Gao J, Sharma P, Tannir NM, Sircar K, Jonasch E. Association of resistance to antiangiogenic therapy with an immunosuppressive tumor microenvironment in metastatic renal cell carcinoma. GU ASCO Annual Meeting, 2015.
21. Mmeje CO, Benson C, Nogueras-Gonzalez GM, Jayaratna IS, Navai N, Gao J, Siefker-Radtke AO, Kamat AM, Dinney CP, Shay JB. Determining the optimal timing for radical cystectomy after neoadjuvant chemotherapy. ASCO Annual Meeting, 2015.
22. Liu X, Hoang A, Zhou L, Kalra S, Yetil A, Sun M, Ding Z, Tamboli P, Rao P, Karam JA, Wood CG, Matin SF, Zurita AJ, Bex A, Griffioen AW, Gao J, Sharma P, Tannir NM, Sircar K, Jonasch E. Association of resistance to antiangiogenic therapy with an immunosuppressive tumor microenvironment in metastatic renal cell carcinoma. J Clin Oncol 33 (suppl 7) , 2015.
23. Gao JJ, Yao H, Su X, Xiong L, Rao P, Sharma P, Karam JA, Wood C, and Tannir NM. Molecular Characterization of Renal Medullary Carcinoma (RMC). J Clin Oncol 32 (5s) , 2014.
24. Gao JJ, Yao H, Su X, Xiong L, Rao P, Sharma P, Karam JA, Wood C, and Tannir NM. Molecular characterization of renal medullary carcinoma (RMC). ASCO Annual Meeting, 2014.
25. Gao JJ, Chen H, Ng Tang D,Sharma P. A study of genes and microRNAs that may predict clinical responses to anti-CTLA-4 therapy. J Clin Oncol 31 (suppl 6) , 2013.
26. Gao JJ, Chen H, Ng Tang D,Sharma P. A study of genes and microRNAs that may predict clinical responses to anti-CTLA-4 therapy. GU ASCO Annual Meeting, 2013.
27. Gao J, Chen H, Ng Tang D, Sharma P. Investigating genes and micro-RNAs that may predict clinical benefits of anti-CTLA-4 therapy. ASCO Annual Meeting, 2013.
28. Gao J, Chen H, Ng Tang D, Sharma P. Investigating genes and micro-RNAs that may predict clinical benefits of anti-CTLA-4 therapy. J Clin Oncol (suppl) , 2013.
29. Gao JJ, Chen H, Ng Tang D,Sharma P. Investigating genes and pathways that play a role in immune responses mediated by anti-CTLA-4 therapy. J Clin Oncol 30 (Suppl) , 2012.
30. Gao J, Sung J, Ward JF, Rao P, Troncoso P, Araujo JC, Tang DN, Chen H, Thall P, Wen S, Sharma P. Combination therapy with anti-CTLA-4 plus leuprolide acetate in the pre-surgical setting of patients with regional, high-risk prostate cancer. Cancer Res 72 (8 suppl) , 2012.
31. Gao JJ, Chen H, Ng Tang D,Sharma P. Investigating genes and pathways that play a role in immune responses mediated by anti-CTLA-4 therapy. ASCO Annual Meeting, 2012.
32. Gao J, Sung J, Ward JF, Rao P, Troncoso P, Araujo JC, Tang DN, Chen H, Thall P, Wen S, Sharma P. Combination therapy with anti-CTLA-4 plus leuprolide acetate in the pre-surgical setting of patients with regional, high-risk prostate cancer. AACR Annual Meeting, 2012.
33. Gao J, McAuliffe JC, Lazar JF, Wang W, Choi H, Hunt K, Araujo DM, Pollock RE, Benjamine RS, Trent JC. Mechanism of early radiographic response to imatinib in GIST. J Clin Oncol 29 (suppl) , 2011.
34. Gao J, McAuliffe JC, Lazar JF, Wang W, Choi H, Hunt K, Araujo DM, Pollock RE, Benjamine RS, Trent JC. Mechanism of early radiographic response to imatinib in GIST. ASCO Annual Meeting, 2011.
35. Choi H, McAuliffe JC, Boonsirikamchai P, Gao JJ, Charnsangavej C, Reynosa DG, Benjamin RS, Trent J. Exploration of the Molecular Mechanism of CT Evidence of Response to Imatinib in Gastrointestinal Stromal Tumors. RSNA, 2011.
36. Tan, X., Shen, J., Papasian, C.J., Morrison, D.C, Qureshi, N. and Gao, J.J. Different mechanisms mediate synergistic production of TNF-a and nitric oxide from mouse macrophages in response to bacterial LPS and peptidoglycan. Shock 23 (suppl) , 2005.
37. Tan, X., Qureshi, N., Morrison, D.C. and Gao, J.J. Bacterial CpG DNA activates transcription factor C/EBP-delta in mouse macrophages. Shock 19 (suppl) , 2003.
38. Gao JJ et al.. Microarray analysis of gene expression patterns in bacterial LPS-tolerized mouse macrophages. Shock 19 (suppl) , 2003.
39. Morrison DC, Zhang G, Shen J, Huo K, Li Y, Shar A, Xue Q, Parmely MJ, Qureshi N, Papasian CJ, Van Way C, Gao JJ. Bacterial LPS and peptidoglycan induce synergistic production of TNF-a and nitric oxide in mouse macrophages via different mechanisms. Shock 17, 2002.
40. Dhar A, Gao JJ, Morrison DC, Qureshi N, Ray BK, Ray A, Van Way C. Involvement of inflammatory transcription factors on apoptosis following hemorrhage. FASEB, 2002.

Book Chapters

1. Sharma P, Subudhi S, Peggs K, Goswami S, Gao J, Quezada S, Allison JP. Cancer Immunotherapy. In: Holland-Frei Cancer Medicine. 9th. Wiley Blackwell, 2017.
2. Shnyra A, Luchi M, Gao JJ et al. Endotoxin in human disease and its endogenious control. In: Multiple Organ Failure. Springer-Verlag New York Inc: New York, 114-130, 2000.